Zeleris

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
30-05-2017
产品特点 产品特点 (SPC)
30-05-2017
公众评估报告 公众评估报告 (PAR)
30-05-2017

有效成分:

florfenicol, meloxicam

可用日期:

CEVA Santé Animale

ATC代码:

QJ01BA99

INN(国际名称):

florfenicol, meloxicam

治疗组:

Cattle

治疗领域:

Amphenicols, combinations, Antibacterials for systemic use

疗效迹象:

For therapeutic treatment of bovine respiratory disease (BRD) associated with pyrexia due to Mannheimia haemolytica, Pasteurella multocida and Histophilus somni susceptible to florfenicol.

授权状态:

Authorised

授权日期:

2017-05-15

资料单张

                                16
B. PACKAGE LEAFLET
17
PACKAGE LEAFLET
ZELERIS 400 MG/ML + 5 MG/ML
SOLUTION FOR INJECTION FOR CATTLE
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
FRANCE
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Zeleris 400 mg/ml + 5 mg/ml solution for injection for cattle
florfenicol / meloxicam
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
1 ml contains 400 mg of florfenicol and 5 mg of meloxicam.
Clear yellow solution.
4.
INDICATION
For therapeutic treatment and of bovine respiratory disease (BRD)
associated with pyrexia due to
_Mannheimia haemolytica_
,
_Pasteurella multocida _
and
_Histophilus somni_
susceptible to florfenicol.
5.
CONTRAINDICATIONS
Do not use in adult bulls intended for breeding.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or when there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substances or to
any of the excipients.
6.
ADVERSE REACTIONS
Injection site reactions (mostly swelling, induration, heat and pain)
were very commonly observed
after subcutaneous administration of the product. These effects were
transitory and usually resolved
without any treatment within 5 to 15 days, but could persist up to 49
days.
During injection of this product animals may exhibit signs of moderate
pain, manifested as movement
of the head or neck.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals
treated)
- rare (more than 1 but less than 10 animals in 10,000 animals
treated)
- very rare (less than 1 a
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Zeleris 400 mg/ml + 5 mg/ml solution for injection for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCES:
Florfenicol
400 mg
Meloxicam
5 mg.
EXCIPIENTS:
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For therapeutic treatment of bovine respiratory disease (BRD)
associated with pyrexia due to
_Mannheimia haemolytica_
,
_Pasteurella multocida _
and
_Histophilus somni_
susceptible to florfenicol.
4.3
CONTRAINDICATIONS
Do not use in adult bulls intended for breeding.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or when there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substances or to
any of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Whenever possible, the veterinary medicinal product should only be
used based on susceptibility
testing. Official, national and regional antimicrobial policies should
be taken into account when the
veterinary medicinal product is used.
Avoid use in severely dehydrated, hypovolaemic or hypotensive animals,
as there may be a potential
risk of renal toxicity. In the absence of safety data it is not
recommended to use the product in calves
less than 4 weeks old.
3
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
The product is slightly irritant to the eye. Rinse any splashes from
eyes immediately with plenty of
water.
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or
the label to the physician.
People with known hypersensitivity to florfenicol, meloxicam or to any
of th
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 30-05-2017
产品特点 产品特点 保加利亚文 30-05-2017
公众评估报告 公众评估报告 保加利亚文 30-05-2017
资料单张 资料单张 西班牙文 30-05-2017
产品特点 产品特点 西班牙文 30-05-2017
公众评估报告 公众评估报告 西班牙文 30-05-2017
资料单张 资料单张 捷克文 30-05-2017
产品特点 产品特点 捷克文 30-05-2017
公众评估报告 公众评估报告 捷克文 30-05-2017
资料单张 资料单张 丹麦文 30-05-2017
产品特点 产品特点 丹麦文 30-05-2017
公众评估报告 公众评估报告 丹麦文 30-05-2017
资料单张 资料单张 德文 30-05-2017
产品特点 产品特点 德文 30-05-2017
公众评估报告 公众评估报告 德文 30-05-2017
资料单张 资料单张 爱沙尼亚文 30-05-2017
产品特点 产品特点 爱沙尼亚文 30-05-2017
公众评估报告 公众评估报告 爱沙尼亚文 30-05-2017
资料单张 资料单张 希腊文 30-05-2017
产品特点 产品特点 希腊文 30-05-2017
公众评估报告 公众评估报告 希腊文 30-05-2017
资料单张 资料单张 法文 30-05-2017
产品特点 产品特点 法文 30-05-2017
公众评估报告 公众评估报告 法文 30-05-2017
资料单张 资料单张 意大利文 30-05-2017
产品特点 产品特点 意大利文 30-05-2017
公众评估报告 公众评估报告 意大利文 30-05-2017
资料单张 资料单张 拉脱维亚文 30-05-2017
产品特点 产品特点 拉脱维亚文 30-05-2017
公众评估报告 公众评估报告 拉脱维亚文 30-05-2017
资料单张 资料单张 立陶宛文 30-05-2017
产品特点 产品特点 立陶宛文 30-05-2017
公众评估报告 公众评估报告 立陶宛文 30-05-2017
资料单张 资料单张 匈牙利文 30-05-2017
产品特点 产品特点 匈牙利文 30-05-2017
公众评估报告 公众评估报告 匈牙利文 30-05-2017
资料单张 资料单张 马耳他文 30-05-2017
产品特点 产品特点 马耳他文 30-05-2017
公众评估报告 公众评估报告 马耳他文 30-05-2017
资料单张 资料单张 荷兰文 30-05-2017
产品特点 产品特点 荷兰文 30-05-2017
公众评估报告 公众评估报告 荷兰文 30-05-2017
资料单张 资料单张 波兰文 30-05-2017
产品特点 产品特点 波兰文 30-05-2017
公众评估报告 公众评估报告 波兰文 30-05-2017
资料单张 资料单张 葡萄牙文 30-05-2017
产品特点 产品特点 葡萄牙文 30-05-2017
公众评估报告 公众评估报告 葡萄牙文 30-05-2017
资料单张 资料单张 罗马尼亚文 30-05-2017
产品特点 产品特点 罗马尼亚文 30-05-2017
公众评估报告 公众评估报告 罗马尼亚文 30-05-2017
资料单张 资料单张 斯洛伐克文 30-05-2017
产品特点 产品特点 斯洛伐克文 30-05-2017
公众评估报告 公众评估报告 斯洛伐克文 30-05-2017
资料单张 资料单张 斯洛文尼亚文 30-05-2017
产品特点 产品特点 斯洛文尼亚文 30-05-2017
公众评估报告 公众评估报告 斯洛文尼亚文 30-05-2017
资料单张 资料单张 芬兰文 30-05-2017
产品特点 产品特点 芬兰文 30-05-2017
公众评估报告 公众评估报告 芬兰文 30-05-2017
资料单张 资料单张 瑞典文 30-05-2017
产品特点 产品特点 瑞典文 30-05-2017
公众评估报告 公众评估报告 瑞典文 30-05-2017
资料单张 资料单张 挪威文 30-05-2017
产品特点 产品特点 挪威文 30-05-2017
资料单张 资料单张 冰岛文 30-05-2017
产品特点 产品特点 冰岛文 30-05-2017
资料单张 资料单张 克罗地亚文 30-05-2017
产品特点 产品特点 克罗地亚文 30-05-2017
公众评估报告 公众评估报告 克罗地亚文 30-05-2017

搜索与此产品相关的警报

查看文件历史